Erschienen in:
01.03.2016 | Editorial
Bisphosphonate drug holidays: we reap what we sow
verfasst von:
S. L. Silverman, J. D. Adachi, E. Dennison, And the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group
Erschienen in:
Osteoporosis International
|
Ausgabe 3/2016
Einloggen, um Zugang zu erhalten
Excerpt
The concept that our patients need to interrupt or stop bisphosphonate therapy for osteoporosis after 5 years of oral bisphosphonate therapy and after 3 years of intravenous bisphosphonate therapy has gained considerable traction worldwide. It has been our observation that some physicians (and even entire health authority regions) are automatically stopping bisphosphonates in patients who are taking osteoporosis medication without consideration for the patient’s risk of fracture. In addition, some physicians have mistakenly extended this concept to other antiresorptives such as raloxifene and denosumab where bone density gains are quickly lost with discontinuation. …